Drug Patents owned by Gilead Sciences Inc

1. List of Biktarvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(10 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(10 years from now)

US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 4 days ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(12 years from now)

US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
New Patient Population (NPP) Jun 18, 2022
M Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

2. List of Complera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(2 months from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(5 months ago)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(2 years from now)

US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's patent expiration?
More Information on Dosage

3. List of Descovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 4 days ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2024
New Indication (I) Oct 3, 2022

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: Treatment of hiv-1 infection; Prophylaxis of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's patent expiration?
More Information on Dosage

4. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US9757406

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10086011

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
M Apr 27, 2025
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage

5. List of Genvoya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 4 days ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Harvoni drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(10 years from now)

US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 28, 2026
New Dosing Schedule (D) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks

Dosage: PELLETS;ORAL

More Information on Dosage

7. List of Odefsey drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(2 months from now)

US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 4 days ago)

US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(5 months ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's patent expiration?
More Information on Dosage

8. List of Sovaldi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9549941 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9549941

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin; For the treatment of hepatitis c

Dosage: PELLETS;ORAL

How can I launch a generic of SOVALDI before it's patent expiration?
More Information on Dosage

9. List of Stribild drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US9891239 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 27 August, 2012

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of STRIBILD before it's patent expiration?
More Information on Dosage

10. List of Tybost drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374 GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 22, 2026
New Patient Population (NPP) Aug 22, 2022

Drugs and Companies using COBICISTAT ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET;ORAL

How can I launch a generic of TYBOST before it's patent expiration?
More Information on Dosage

11. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(6 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(8 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(8 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(13 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

12. List of Vemlidy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 4 days ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M Aug 22, 2023
New Patient Population (NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 10 November, 2016

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: TABLET;ORAL

How can I launch a generic of VEMLIDY before it's patent expiration?
More Information on Dosage

13. List of Vitekta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

Drugs and Companies using ELVITEGRAVIR ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

14. List of Vosevi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

15. List of Zydelig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44638 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Aug, 2025

(2 years from now)

US10730879 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US8865730 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US9469643 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149477 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
May, 2025

(2 years from now)

US8980901 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
May, 2025

(2 years from now)

USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Jul, 2025

(2 years from now)

US9492449 GILEAD SCIENCES INC Therapies for hematologic malignancies
Mar, 2030

(7 years from now)

Drugs and Companies using IDELALISIB ingredient

Market Authorisation Date: 23 July, 2014

Treatment: Inhibition on pi3k kinase; For the treatment of patients with cll, fl, or sll; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

How can I launch a generic of ZYDELIG before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in